Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19460804 | 1.00 | ACE (0.43) | ACEOPRM1OPRD1OPRK1POLB | |
| SCHEMBL17559433 | 1.00 | ACE (0.43) | ACEOPRM1OPRD1OPRK1POLB | |
| SCHEMBL17559463 | 1.00 | ACE (0.43) | ACEOPRM1OPRD1OPRK1POLB | |
| SCHEMBL17559368 | 1.00 | ACE (0.43) | ACEOPRM1OPRD1OPRK1POLB | |
| SCHEMBL19460646 | 1.00 | ACE (0.43) | ACEOPRM1OPRD1OPRK1POLB | |
| SCHEMBL19460801 | 1.00 | ACE (0.43) | ACEOPRM1OPRD1OPRK1POLB | |
| SCHEMBL17559367 | 1.00 | ACE (0.43) | ACEOPRM1OPRD1OPRK1POLB | |
| SCHEMBL25350020 | 0.87 | ACE (0.44) | ACEOPRM1OPRD1OPRK1POLB | |
| SCHEMBL25350023 | 0.87 | ACE (0.44) | ACEOPRM1OPRD1OPRK1POLB | |
| SCHEMBL25355545 | 0.87 | ACE (0.44) | ACEOPRM1OPRD1OPRK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493438-B | Tetrahydroisoquinoline compounds | 南京再明医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230250108-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| EP-4174064-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AND USE THEREOF | Jiangsu Simcere Pharmaceutical Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| CN-113493438-A | Tetrahydroisoquinoline compounds | 江苏先声药业有限公司 | 2021-10-12 | — | — | CN | disclosed |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2021-06-08 | — | — | US | disclosed |
| EP-3426648-B1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2021-05-12 | — | — | EP | disclosed |
| EP-3426635-B1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3189041-B1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-04-28 | — | — | EP | disclosed |
| EP-3426351-B1 | BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-12-09 | — | — | EP | disclosed |
| EP-3426647-A1 | TETRAHYDROISOQUINOLINES AS PRMT5-INHIBITORS | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| EP-3426635-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| EP-3426648-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153519-A1 | 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153520-A1 | BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153515-A1 | TETRAHYDROISOQUINOLINES AS PRMT5-INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| EP-3189041-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | Ctxt Pty Ltd (AU) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250108-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AND USE THEREOF | PRMT5, PRMT1, PRMT3 | ACE 2318/4885OPRM1 4353/4885OPRD1 4244/4885 |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | ACE 2484/4885OPRM1 1801/4885OPRD1 1573/4885 |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBZ, HBG2 | ACE 4677/4885OPRM1 61/4885OPRD1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.